Larry Ramer

Larry Ramer

InvestorPlace Contributor

Larry Ramer has more than 15 years of experience in business journalism. He has worked for Globes, Israel’s most widely read business newspaper, as well as The Jerusalem Post and theflyonthewall.

Mr. Ramer’s expansive knowledge of politics enables him to provide valuable insights into how politics can affect stocks. He also focuses on contrary investing and specializes in the renewable energy and consumer discretionary sectors.

Among his highly successful, contrarian picks have been Super Micro Computer, Intel, and MGM Resorts.

You can reach him on StockTwits at @larryramer and learn more about his stock-picking record at his TipRanks profile.

Recent Articles

Gilead Gets a Boost From Positive Coronavirus Research

By Larry Ramer, InvestorPlace Contributor

Signs continue to mount that remdesivir is a highly effective treatment for the coronavirus. The drug will move the needle for GILD stock.

DraftKings Stock Will Keep Benefitting from Multiple Strong Trends

By Larry Ramer, InvestorPlace Contributor

DraftKings stock will be boosted by the popularity of iGaming and the resumption of professional sports leagues

Microsoft Stock Will Gain from Strong, Positive Catalysts

By Larry Ramer, InvestorPlace Contributor

Microsoft stock has multiple, positive catalysts over the short term and the long term. These catalysts will push the shares higher.

Co-Diagnostics Stock Will Be Weighed Down by Multiple Issues

By Larry Ramer, InvestorPlace Contributor

There's evidence that Co-Diagnostics' test is not as accurate as many of its competitors' offerings. That makes CODX stock quite risky.

Why Moderna Stock Looks Quite Risky

By Larry Ramer, InvestorPlace Contributor

Data from the Phase 1 trial of Moderna's coronavirus vaccine was mixed, making MRNA stock risky at its current levels.

Load More